MS BioNTech WKN: A2PSR2 ISIN: US09075V1026 Forum: Aktien User: Thekla
Die Daten zur Kollaboration mit DualityBio, die zur ASCO Konferenz vorgestellt werden, haben alleine schon das Potenzial für einen turnaround: „Building on this data, we are planning to start a phase 3 clinical trial in non-small cell lung cancer patients without driver mutations who have progressed following anti-PD-1. After progressing on an anti-PD-1 treatment, non-small cell lung cancer patients have eight to 11 months median overall survival and three to 4.5 months progression-free survival, with a response rate of around 10% when treated with the second-line standard of care docetaxel. With ONC-392, we hope to offer a promising new second-line treatment option for these patients. The randomized open-label controlled multicenter phase 3 PRESERVE-003 study is planned to treat IO-resistant non-small cell lung cancer patients. In the dose confirmation part, we and OncoC4 plan to assess the efficacy and safety of ONC-392 given at two dose levels in comparison to docetaxel. In the subsequent part of the trial, we intend to assess the safety and efficacy of ONC-392 at selected dose regimen versus docetaxel in patients with stage 4 non-small cell lung cancer who progressed on prior IO treatment with or without chemotherapy and equal stages of 0 or 1 can be enrolled. Prior IO-IO therapy is allowed. A total of about 600 patients are planned to be enrolled and randomized one-to-one to receive either ONC-392 or docetaxel in this two-stage study. The primary endpoint is overall survival, with objective response rate, PFS, and safety as secondary endpoints. The study is planned to start enrolling patients within the next few weeks. A Trial in Progress poster will be presented at the 2023 ASCO annual meeting.“
Dann gleich noch etwas Pfizer investiert COVID-Gewinne in den Kampf gegen den Krebs, sagt CEO Bourla Pfizer hat angekündigt, den Preis seiner COVID-Impfung in diesem Jahr voraussichtlich auf etwa 110 bis 130 US-Dollar pro Dosis zu vervierfachen. 11. Mai 2023 19:07 Uhr https://www.reuters.com/business/healthcare-pharmaceuticals/pfizer-pouring-covid-profits-into-cancer-battle-ceo-bourla-says-2023-05-11/ .
Mehr zu diesem Wert
|
|
Thema | ||
|---|---|---|---|
| 1 | HauptForum SK HYNIC | +6,45 % | |
| 2 | BYD - Presselinks | -1,65 % | |
| 3 | Trading- und Aktien-Chat | ||
| 4 | für alle, die es ehrlich meinen beim Traden. | ||
| 5 | Freunde der Telekom | -0,79 % | |
| 6 | YNVISIBLE INTERACTIVE Hauptdiskussion | -2,58 % | |
| 7 | PlasCred Circular Innovations | -0,62 % | |
| 8 | Ocugen Aktienforum Hauptdiskussion | +5,12 % | |
| 9 | Metaplanet | -5,87 % | |
| 10 | DRONESHIELD LTD Hauptdiskussion | +2,10 % | Alle Diskussionen |
|
|
Thema | ||
|---|---|---|---|
| 1 | HauptForum SK HYNIC | +6,45 % | |
| 2 | BYD - Presselinks | -1,65 % | |
| 3 | Freunde der Telekom | -0,79 % | |
| 4 | YNVISIBLE INTERACTIVE Hauptdiskussion | -2,58 % | |
| 5 | PlasCred Circular Innovations | -0,62 % | |
| 6 | Ocugen Aktienforum Hauptdiskussion | +5,12 % | |
| 7 | Metaplanet | -5,87 % | |
| 8 | DRONESHIELD LTD Hauptdiskussion | +2,10 % | |
| 9 | VW Hauptdiskussion | -0,80 % | |
| 10 | Critical Infrastructure Technologies Hauptdiskussion | +2,41 % | Alle Diskussionen |